Skip to main content
SpringerLink
Log in

Ocular Cicatricial Pemphigoid

  • Chapter
  • First Online:
Autoimmune Bullous Diseases

  • 826 Accesses

Abstract

Ocular cicatricial pemphigoid is a result of immune dysfunction leading to deposition of immunoglobulins and complement at the conjunctival basement membrane zone. This can lead to irreversible scarring. Patients are treated with suitable systemic immunomodulatory treatments which are usually individualized to the patient depending on the patient’s age, disease stage, and presence of non-ocular symptoms. The approach to choosing the proper chemotherapy is through a stepladder algorithm. The ultimate goal of therapy is to treat the patient with corticosteroid-sparing systemic agent. The focus of this chapter will be the medical treatment strategies available for OCP based upon clinical severity, extent and progression of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Neff AG, Turner M, Mutasim DF. Treatment strategies in mucous membrane pemphigoid. Ther Clin Risk Manag. 2008;4(3):617–26.

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Higgins GT, Allan RB, Hall R, et al. Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa. Br J Ophthalmol. 2006;90:964–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Kirzhner M, Jakobiec FA. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis and current management. Semin Ophthalmol. 2011;26(4–5):270–7.

    Article  PubMed  Google Scholar 

  4. Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res. 2004;23(6):579–92.

    Article  PubMed  Google Scholar 

  5. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–663.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 1982;89:340–53.

    Article  CAS  PubMed  Google Scholar 

  7. Chan RY, Bhol K, Tesavibul N, et al. The role of antibody to human beta 4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest Ophthamol Vis Sci. 1999;40:2283–90.

    CAS  Google Scholar 

  8. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology. 1999;106:2136–43.

    Article  CAS  PubMed  Google Scholar 

  9. Dantzig PI. Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol. 1974;110:393–406.

    Article  CAS  PubMed  Google Scholar 

  10. Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology. 1981;88:95–100.

    Article  CAS  PubMed  Google Scholar 

  11. Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol. 1992;82:223–9.

    Article  CAS  PubMed  Google Scholar 

  12. Stephens CR. The structure of aureomycin. J Am Chem Soc. 1954;76:3568–75.

    Article  CAS  Google Scholar 

  13. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258–65.

    Article  PubMed  Google Scholar 

  14. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by sub-minimal inhibitory concentrations of tetracyclines and erythromycin. Antimicrob Agents Chemother. 1982;21:770–2.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25:133–5.

    Article  CAS  PubMed  Google Scholar 

  16. Poskitt L, Wojnarowska F. Treatment of cicatricial pemphigoid with tetracycline and nicotinamide. Clin Exp Dermatol. 1995;20:258–9.

    Article  CAS  PubMed  Google Scholar 

  17. Mallon E, Wojnarowska F. Cicatricial pemphigoid presenting with unusual palmar involvement, successfully treated with a combination of nicotinamide and tetracycline. Clin Exp Dermatol. 1994;19:526–30.

    Article  CAS  PubMed  Google Scholar 

  18. Kohler IK, Lorincz AL. Erythema elevatum diutinum treated with niacinamide and tetracycline. Arch Dermatol. 1980;116:693–5.

    Article  CAS  PubMed  Google Scholar 

  19. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide a preliminary report. Arch Dermatol. 1986;122:670–4.

    Article  CAS  PubMed  Google Scholar 

  20. Thornfeldt CR, Menkes AW. Bullous pemphigoid controlled by tetracycline. J Am Acad Dermatol. 1987;16:305–10.

    Article  CAS  PubMed  Google Scholar 

  21. Pereyo NG, Davis LS. Generalized bullous pemphigoid controlled by tetracycline therapy alone. J Am Acad Dermatol. 1995;32(1):138–9.

    Article  CAS  PubMed  Google Scholar 

  22. Smith CJ, Sayles H, Mikuls TR, Michaud K. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. Arthritis Res Ther. 2011;13:2–8.

    Article  CAS  Google Scholar 

  23. Fourneau E. Action antistreptococcique des dérivés sulfurés organiques. CE Acad Sci. 1937;204:1763.

    CAS  Google Scholar 

  24. Rook A, Waddington E. Pemphigus and pemphigoid. Br J Dermatol. 1953;65:425–31.

    Article  Google Scholar 

  25. Persons JR, Rogers RS. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol. 1977;113:610–5.

    Article  Google Scholar 

  26. Wertheim MS, Males JJ, Cook SD, et al. Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid. Br J Ophthalmol. 2006;90:516.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Fern AI, Jay JL, Young H, et al. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmology. 1992;76:332–5.

    Article  CAS  Google Scholar 

  28. Doan S, Lerouic JF, Robin H, et al. Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology. 2001;108:1565–8.

    Article  CAS  PubMed  Google Scholar 

  29. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic antagonist 4-aminopteroglutamic acid (aminopterin). N Engl J Med. 1948;238:787–93.

    Article  CAS  PubMed  Google Scholar 

  30. Wong VG. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:279–93.

    Google Scholar 

  31. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13:335–51.

    Article  CAS  PubMed  Google Scholar 

  32. Kaplan-Messas A, Barkana Y, Avni I, et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11:131–9.

    Article  CAS  PubMed  Google Scholar 

  33. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992;99:1419–23.

    Article  CAS  PubMed  Google Scholar 

  34. Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–9.

    Article  CAS  PubMed  Google Scholar 

  35. Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol In Flamm. 2001;9:35–40.

    Article  CAS  Google Scholar 

  36. Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br K Ophthalmol. 2005;89:806–8.

    Article  CAS  Google Scholar 

  37. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008;47:249–55.

    Article  CAS  Google Scholar 

  38. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Saw VP, Dart JK. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf. 2008;6:128–42.

    Article  PubMed  Google Scholar 

  40. Van Ede AE, Laan RF, Blom HJ, et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998;27:277–97.

    Article  PubMed  Google Scholar 

  41. Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993;36:329–35.

    Article  CAS  PubMed  Google Scholar 

  42. Tolman KG, Clegg DO, Lee RG, et al. Methotrexate and the liver. J Rheumatol Suppl. 1985;12:29–34.

    PubMed  Google Scholar 

  43. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:423–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Lahdenne P, Rapola J, Ylijoki H, et al. Hepatoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. J Rheumatol. 2002;29:2442–5.

    CAS  PubMed  Google Scholar 

  45. Suwa A, Hirakata M, Satoh S, et al. Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy. Clin Exp Rheumatol. 1999;17:355–8.

    CAS  PubMed  Google Scholar 

  46. Salaffi F, Manganelli P, Carotti M, et al. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol. 1997;16:296–304.

    Article  CAS  PubMed  Google Scholar 

  47. Cottin V, Tébib J, Massonnet B, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest. 1996;109:933–9.

    Article  CAS  PubMed  Google Scholar 

  48. Hilliquin P, Renoux M, Perrot S, et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol. 1996;35:441–5.

    Article  CAS  PubMed  Google Scholar 

  49. Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146:802–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology. 2002;109:111–8.

    Article  PubMed  Google Scholar 

  51. Baker KB, Spurrier NJ, Watkins AS, et al. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol. 2006;90:1481–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology. 1998;57:51–5.

    Article  CAS  PubMed  Google Scholar 

  53. Lewden B, Vial T, Elefant E, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 2004;31:2360–5.

    CAS  PubMed  Google Scholar 

  54. Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Elion GB. The purine path to chemotherapy. Science. 1989;244(4900):41–7.

    Article  CAS  PubMed  Google Scholar 

  56. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55(3):369–89.

    Article  PubMed  Google Scholar 

  57. Elion GB, Callahan SW, Hitchings GH, et al. The metabolism of 2-amino-6-(1-methyl-4-nitro-5-imidazolyl) thiopurine (B.W. 57–323) in man. Cancer Chemother Rep 1. 1960;8:47–52.

    CAS  Google Scholar 

  58. Thiersch JB. Effect of 6-(1'-methyl-4'-nitro-5'-imidazolyl)-mercaptopurine and 2-amino-6-(1'-methyl-4'-nitro-5'-imidazolyl)-mercaptopurine on the rat litter in utero. J Reprod Fertil. 1962;4:297–302.

    Article  CAS  PubMed  Google Scholar 

  59. Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. New Engl J Med. 1963;268(24):1315–23.

    Article  CAS  PubMed  Google Scholar 

  60. Dave VK, Vickers CF. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol. 1974;90:183–6.

    Article  CAS  PubMed  Google Scholar 

  61. Ward JR. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis. Am J Med. 1988;85:39–44.

    Article  CAS  PubMed  Google Scholar 

  62. Danovitch GM. Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients. Transplant Proc. 1999;31:2S–6.

    Article  CAS  PubMed  Google Scholar 

  63. Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther. 2007;20:206–15.

    Article  PubMed  Google Scholar 

  64. Gisbert JP, Niño P, Cara C, et al. Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther. 2008;28:228–38.

    Article  CAS  PubMed  Google Scholar 

  65. Lee JC, Gladman DD, Schentag CT, et al. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7:160–5.

    Article  CAS  PubMed  Google Scholar 

  66. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696–701.

    Article  CAS  PubMed  Google Scholar 

  67. Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1999;99:443–6.

    Google Scholar 

  68. Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110:1061–5.

    Article  PubMed  Google Scholar 

  69. Behrend M. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Clin Nephrol. 1996;45:336–41.

    PubMed  Google Scholar 

  70. Zurdel J, Aboalchamat B, Zierhut M, et al. Early clinical experiences with mycophenolate mofetil for immunosuppressive therapy of ocular cicatricial pemphigoid [in German]. Klin Monbl Augenheilkd. 2001;218:222–8.

    Article  CAS  PubMed  Google Scholar 

  71. Larkin G, Lightman S. Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999;106:370–4.

    Article  CAS  PubMed  Google Scholar 

  72. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225–32.

    Article  CAS  PubMed  Google Scholar 

  73. Boumpas DT, Kritikos HD, Daskalakis NG. Perspective on future therapy of vasculitis. Curr Rheumatol Rep. 2000;2:423–9.

    Article  CAS  PubMed  Google Scholar 

  74. Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus. 2001;10:203–8.

    Article  CAS  PubMed  Google Scholar 

  75. Meihsler W, Reinisch W, Moser G, et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn’s disease? Am J Gastroenterol. 2001;96:782–7.

    Article  Google Scholar 

  76. Schwarz A. New aspects of the treatment of nephrotic syndrome. J Am Soc Nephrol. 2001;12 Suppl 17:S44–7.

    PubMed  Google Scholar 

  77. Chanaud III NP, Vistica BP, Eugui E, et al. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res. 1995;61:429–34.

    Article  CAS  PubMed  Google Scholar 

  78. Budde K, Glander P, Bauer S, et al. Pharmacodynamic monitoring of mycophenloate mofetil. Clin Chem Lab Med. 2000;38:1213–6.

    Article  CAS  PubMed  Google Scholar 

  79. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation. 2001;72:245–50.

    Article  CAS  PubMed  Google Scholar 

  80. Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Am Acad Ophthalmology. 2005;112:1472–7.

    Article  Google Scholar 

  81. Doycheva D, Deuter C, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm. 2011;19:431–8.

    Article  CAS  PubMed  Google Scholar 

  82. Nottage JM, Hammersmith KM, Murchison AP, et al. Treatment of mucous membrane pemphigoid with mycophenolate mofetil. Cornea. 2013;32(6):810–5.

    Article  PubMed  Google Scholar 

  83. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. 2008;115:253–61.

    Article  PubMed  Google Scholar 

  85. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115:1826–32.

    Article  PubMed  Google Scholar 

  86. Pleyer U, Ruokonen P, Schmidt N, et al. Mycophenol acid in ocular autoimmune disorders-can we optimize this therapy? [in German]. Klin Monbl Augenheilkd. 2008;225:66–9.

    Article  CAS  PubMed  Google Scholar 

  87. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis [letter]. Lancet. 1998;352:35–6.

    Article  CAS  PubMed  Google Scholar 

  88. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nature Reviews. Clin Oncol. 2009;6(11):638–47.

    CAS  Google Scholar 

  89. Elder MJ, Jones RJ, Brodsky RA. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmology. 1995;79:264–6.

    Article  CAS  Google Scholar 

  90. Roda PE. Nitrogen mustard therapy of uveitis of unknown etiology. Rev Clin Esp. 1952;44:173–80.

    Google Scholar 

  91. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.

    Article  CAS  PubMed  Google Scholar 

  92. Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide of ocular inflammatory diseases. Ophthalmology. 2010;117(2):356.

    Article  PubMed Central  PubMed  Google Scholar 

  93. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991;35:369–85.

    Article  CAS  PubMed  Google Scholar 

  94. Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology. 1990;97:939–52.

    Article  CAS  PubMed  Google Scholar 

  95. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea. 1991;10:185–95.

    Article  CAS  PubMed  Google Scholar 

  96. Yesudian PD, Armstrong S, Cawood JI, et al. Mucous membrane pemphigoid: management of advanced ocular disease with intravenous cyclophosphamide and amniotic membrane transplantation. Br J Dermatol. 2005;153:692–4.

    Article  CAS  PubMed  Google Scholar 

  97. Pandya AG, Warren KJ, Bergstresser PR. Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide. Arch Dermatol. 1997;133:245–7.

    CAS  PubMed  Google Scholar 

  98. Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–84.

    Article  PubMed Central  PubMed  Google Scholar 

  99. Berkson BM, Lome LG, Shapiro I. Severe cystitis induced by cyclophosphamide, role of surgical management. JAMA. 1973;225:605–6.

    Article  CAS  PubMed  Google Scholar 

  100. Park MC, Park YB, Jung SY, et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus. 2004;13:569–74.

    Article  CAS  PubMed  Google Scholar 

  101. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic disease. J Rheumatol. 1999;26:1705–14.

    CAS  PubMed  Google Scholar 

  102. Baltus JA, Boersma JW, Hartman AP, et al. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis. 1983;42:368–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  103. Baker GL, Kahl LE, Zee BC, et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case–control follow-up study. Am J Med. 1987;83:1–9.

    Article  CAS  PubMed  Google Scholar 

  104. Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol. 1992;28:148–52.

    Article  CAS  PubMed  Google Scholar 

  105. Rubin B, Palestine AG. Complications of corticosteroid and immunosuppressive drugs. Int Ophthalmol Clin. 1989;29(3):159–71.

    Article  CAS  PubMed  Google Scholar 

  106. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis. 2008;52(6):1180–96.

    Article  PubMed  Google Scholar 

  107. Siami GA, Siami FS. Membrane plasmapheresis in the United States: a review over the last 20 years. Ther Apher. 2001;5(4):315–20.

    Article  CAS  PubMed  Google Scholar 

  108. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83–177.

    Article  PubMed  Google Scholar 

  109. Hashimoto Y, Suga Y, Yoshiike T, et al. A case of antiepiligrin cicatricial pemphigoid successfully treated by plasmapheresis. Dermatology. 2000;201:58–60.

    Article  CAS  PubMed  Google Scholar 

  110. Chang B, Tholpady A, Huang R, et al. Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature. Blood Transfus. 2014;12:269–75.

    PubMed Central  PubMed  Google Scholar 

  111. Roujeau JC, Revuz J, Touraine R, et al. Cortico-resistant bullous pemphigoid. Favorable results with plasmapheresis [In French]. Nouv Presse Med. 1979;8:3362.

    CAS  PubMed  Google Scholar 

  112. Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet. 1984;2:486–8.

    Article  CAS  PubMed  Google Scholar 

  113. Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol. 2000;39(3):230–5.

    Article  CAS  PubMed  Google Scholar 

  114. Mazzi G, Raineri A, Zanolli FA, et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apher Sci. 2003;28:13–8.

    Article  PubMed  Google Scholar 

  115. Gurland HJ, Lysaght MJ, Samtleben W, et al. A comparison of centrifugal and membrane-based apheresis formats. Int J Artif Organ. 1984;7(1):35–8.

    CAS  Google Scholar 

  116. Yamada H, Yaguchi H, Takamori K, et al. Plasmapheresis for the treatment of pemphigus vulgaris and bullous pemphigoid. Therupeutic A. 1997;1(2):178–82.

    Article  CAS  Google Scholar 

  117. Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1058–64.

    Article  CAS  PubMed  Google Scholar 

  118. Bohn J, Jonsson S, Holst R. Successful treatment of recalcitrant cicatricial pemphigoid with a combination of plasma exchange and cyclophosphamide. Br J of Dermatol. 1999;141:536–40.

    Article  CAS  Google Scholar 

  119. Hashimoto Y, Suga Y, Yoshiike T, et al. A case of antiepiligrin cicatricial successfully treated by plasmapheresis. Dermatology. 2001;201:58–60.

    Article  Google Scholar 

  120. Tellier Z. Intravenous immunoglobulin in eye involvement. Clin Rev Allergy Immun. 2005;29:295–306.

    Article  CAS  Google Scholar 

  121. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003;139:1051–9.

    Article  CAS  PubMed  Google Scholar 

  122. Kazatchkine MD. Immunomodulation of autoimmune and inflammatory disease with intravenous immune globulin. N Engl J Med. 2001;345:747–55.

    Article  CAS  PubMed  Google Scholar 

  123. Tellier Z. Human immunoglobulins in intraocular inflammation. Ann NY Acad Sci. 2007;1110:337–47.

    Article  CAS  PubMed  Google Scholar 

  124. Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology. 1991;98:858–62.

    Article  CAS  PubMed  Google Scholar 

  125. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 1983;96:453–9.

    Article  CAS  PubMed  Google Scholar 

  126. Letko E, Miserocchi E, Daoud YJ, et al. A nonradomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol. 2004;111:303–10.

    Article  CAS  PubMed  Google Scholar 

  127. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. Am Acad Ophthalmology. 1999;106:2136–43.

    Article  CAS  Google Scholar 

  128. Sami N, Bhol KC, Razzaque AA, et al. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol. 2002;102:59–67.

    Article  CAS  PubMed  Google Scholar 

  129. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. Am Acad Ophthalmology. 2010;117:861–9.

    Article  Google Scholar 

  130. Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol. 2009;93:421–2, 548.

    Article  CAS  PubMed  Google Scholar 

  131. Schumann T, Schmidt E, Booken N, et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab [letter]. Acta Derm Venereol. 2009;89:101–2.

    Article  PubMed  Google Scholar 

  132. Gurcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9:10–25.

    Article  PubMed  CAS  Google Scholar 

  133. El Tal AK, Posner MR, Spigelman Z, et al. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2006;55:449–59.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massachusetts Eye Research and Surgery Institution, Ocular Immunology and Uveitis Foundation, Cambridge, MA, USA

    Swetha Dhanireddy MD, BS, Armin Maghsoudlou MD, Janine M. Preble MS, Malinga D. Ratwatte BA (Cantab) & C. Stephen Foster MD, FACS, FACR

  2. School of Clinical Medicine, University of Cambridge, Cambridge, Cambridgeshire, UK

    Malinga D. Ratwatte BA (Cantab)

  3. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

    C. Stephen Foster MD, FACS, FACR

Authors
  1. Swetha Dhanireddy MD, BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Armin Maghsoudlou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janine M. Preble MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Malinga D. Ratwatte BA (Cantab)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Stephen Foster MD, FACS, FACR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Stephen Foster MD, FACS, FACR .

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Alabama at Birmingham, BIRMINGHAM, Alabama, USA

    Naveed Sami

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dhanireddy, S., Maghsoudlou, A., Preble, J.M., Ratwatte, M.D., Foster, C.S. (2016). Ocular Cicatricial Pemphigoid. In: Sami, N. (eds) Autoimmune Bullous Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26728-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26728-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26726-5

  • Online ISBN: 978-3-319-26728-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation